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Fanconi anemia (FA) is a recessively inherited disease characterized by multiple symptoms including growth retardation, skeletal
abnormalities, and bone marrow failure. The FA diagnosis is complicated due to the fact that the clinical manifestations are
both diverse and variable. A chromosomal breakage test using a DNA cross-linking agent, in which cells from an FA patient
typically exhibit an extraordinarily sensitive response, has been considered the gold standard for the ultimate diagnosis of FA. In
the majority of FA patients the test results are unambiguous, although in some cases the presence of hematopoietic mosaicism may
complicate interpretation of the data. However, some diagnostic overlap with other syndromes has previously been noted in cases
with Nijmegen breakage syndrome. Here we present results showing that misdiagnosis may also occur with patients suﬀering from
two of the three currently known cohesinopathies, that is, Roberts syndrome (RBS) and Warsaw breakage syndrome (WABS). This
complication may be avoided by scoring metaphase chromosomes—in addition to chromosomal breakage—for spontaneously
occurring premature centromere division, which is characteristic for RBS and WABS, but not for FA.
1.Introduction
Fanconi anemia (FA) is a recessive chromosomal instability
syndrome that is clinically characterized by a wide variety
of symptoms including growth retardation and developmen-
tal abnormalities such as malformed digits, absent radii,
and microcephaly. Additional common features include a
progressive bone marrow failure and pronounced cancer
predisposition. Because the FA phenotype is so diverse and
variable, diagnosis on the basis of clinical features alone is
often diﬃcult [1–3].
The ultimate diagnosis of FA has been based on a
hyperresponsiveness of FA cells to chromosome breakage by
DNA cross-linking agents, such as diepoxybutane (DEB) and
mitomycin C (MMC), or on excessive cell cycle arrest in
the G2/M phase of the cell cycle, both spontaneously and
after treatment with MMC [4–6] .I nan u m b e ro fp a t i e n t s ,
spontaneous genetic reversion can correct FA mutations in
haematopoieticstemcells,leadingtomosaicismintheblood.
The reverted cells may (partially) correct the bone marrow
failure [7–11]. In mosaic FA patients, the overall cross-linker
hypersensitivity is less pronounced, because in the blood of
such patients phenotypically normal cells exist in addition to
FAcells.Asgeneticreversionhasnotbeenobservedintissues
other than blood, performing the test on the patient’s skin
ﬁbroblasts helps to avoid this complication.
An occasional patient suﬀering from Nijmegen breakage
syndrome or some hitherto undeﬁned disorder has been
noted to score positive in the FA chromosomal breakage
test [12–14]. Cellular hypersensitivity to MMC has also been
reported for a distinct class of syndromes, the so-called
“cohesinopathies”. These are caused by mutations in genes
involved in the process of sister chromatid cohesion [15]
and include Cornelia de Lange syndrome, Roberts syndrome
[16–18], and the recently described Warsaw Breakage syn-
drome [19]. Due to a highly variable clinical phenotype,2 Anemia
Roberts syndrome (RBS) patients may exhibit symptoms
overlapping with those of FA. RBS is an extremely rare,
autosomalrecessivedisordercharacterizedbyseverepre-and
postnatalgrowthretardation,craniofacialabnormalities,and
symmetric limb defects, features that are also observed in
FA. RBS is caused by mutations in ESCO2, which encodes
an acetyltransferase that is involved in sister chromatid
cohesion [20]. Aﬀected individuals show varying degrees
of malformations involving symmetric reduction in the
number of digits and the length or presence of bones
in the arms and legs [21]. So far, no clear correlation
between the type of mutation and clinical phenotype
h a sb e e no b s e r v e d[ 22–24]. Most cases of RBS result in
spontaneous abortion, stillbirth, or neonatal death; mental
retardation is often observed, with various degrees of
severity. At the cellular level, RBS patients show speciﬁc
cytogenetic features, mainly consisting of metaphase chro-
mosomes displaying repulsion of heterochromatic regions,
leading to a railroad-track appearance of the chromo-
somes. This cytogenetic feature is used in the diagnosis
of RBS and may be followed by mutational analysis of
ESCO2.
Recently, an individual was described with mutations
in another gene involved in sister chromatid cohesion,
DDX11/ChlR1, which encodes an XPD-like DNA helicase.
This novel cohesinopathy, called Warsaw breakage syndrome
(WABS), is mainly characterized by severe growth retar-
dation and microcephaly [19]. The patient representing
this syndrome was initially suspected to suﬀer from a
chromosomal instability syndrome and was therefore tested
for chromosomal breakage in an FA-speciﬁc diagnostic test.
Metaphase preparations revealed cohesion defects (as in
RBS),thatis,railroad-trackappearanceofchromosomesdue
to premature centromere division (PCD); in addition to this
feature, a high proportion of metaphases showed premature
chromatid separation (PCS), in particular after treatment
with MMC.
HerewereportthatpatientssuﬀeringfromRBSorWABS
maybemisdiagnosedashavingFAbasedonexcessiveMMC-
induced chromosomal breakage in primary lymphocyte
cultures and/or on an increased arrest of primary skin
ﬁbroblasts in the G2/M phase of the cell cycle. However,
detailed cytogenetic analysis of unchallenged lymphocyte
cultures should reveal the presence of railroad track-like
chromosomes in RBS and WABS, which are not known
to occur in unchallenged FA lymphocyte cultures. We
conclude that in the diagnostic work-up for FA, cytogenetic
examination should include the scoring of cohesion defects
in unbanded metaphase preparations, in order to exclude the
cohesinopathies RBS and WABS.
2. Methods
2.1. Patients. All aﬀected individuals investigated (Table 1)
have been reported before. RBS patients with homozygous
mutations in ESCO2 and heterozygous carriers (mothers)
were as follows: VU1174 (c.1457 1458delAG) (Turkey);
VU1199 (c.877 878delAG) (Turkey) and VU1200 (mother
of VU1199); VU1366 (c.762 763delTT) (Tunisia); VU1400
(c.877 878delAG) (The Netherlands) and VU1401
(mother of VU1400) [20, 23, 24]; and WABS patient
VU1202 with biallelic mutations in DDX11 (IVS22+2C>T
and c.2689 2691delAAG) and his mother (VU1203,
IVS22+2C>T) [19]. The FA-J patient EUFA1333 and FA-B
patient EUFA1386 were reported before [25, 26]. Three
healthy individuals (laboratory personnel, ML, NN, and
Bebu) served as controls in the cytogenetic analyses.
2.2. Lymphocyte Chromosomal Breakage Test. Freshly drawn
heparinized venous blood (≥2mL) was used to prepare
whole-blood cultures as usual for routine cytogenetic anal-
ysis. Next to two healthy controls, blood samples were
analyzed from the RBS patients (RBS-1, -2, and -3),
heterozygous mothers (Con-1 and -2), the WABS patient
(WABS) and his heterozygous mother (Con-3), FA-B patient
FA-2, and the mosaic FA-J patient FA-1. Four cultures per
individual were prepared by adding 0.5mL blood to 4.5mL
complete medium (RPMI (Gibco, Grand Island NY, USA)
including 15% fetal bovine serum (Hyclone, Logan, USA)
streptomycin, penicillin (both Gibco), and phytohemag-
glutinin (PHA) as prescribed (Remel inc., Lenexa, USA).
The whole-blood cultures were incubated for 72h with 0,
50, 150, or 300nM mitomycin C (MMC; Kyowa Hakko
Kogyo Co., Tokyo, Japan). After treatment with demecolcin
(Sigma,St.Louis,USA,200ng/mL)for40minutes,cellswere
harvested, incubated with 0.075M KCL for 20 minutes at
roomtemperature,andﬁxedwith75%methanol,25%acetic
acid. Cells were dropped on a microscope slide and stained
for 5 minutes in a 5% Giemsa solution (Merck); no banding
technique was applied. For each culture, 50 metaphases were
examined for chromosomal breakage and cohesion defects,
on coded slides. The presence of chromatid breaks and
interchanges was expressed as break events per cell, counting
chromatid interchange ﬁgures as the minimum number
of break events required for their reconstruction [27].
Metaphases showing cohesion defects were recorded in one
ofﬁvecategories:(1)1-2railroadchromosomes(“railroads”)
per cell, (2) 3–5 railroads per cell, (3) >5 railroads per
cell, (4) >5 railroads plus one or more chromosomes with
total chromatid separation, (5) total premature chromatid
separation (PCS); for illustrations, see Figure 3(b).
2.3. Cell Cycle Analysis of Primary Fibroblasts. Primary skin
ﬁbroblasts from two RBS patients (RBS-1 and -4), the WABS
patient, two FA patients (FA-1 and -2), and a healthy control
were cultured for 72 hours either without or with MMC
(50 or 100nM) in Ham’s F10 medium (Gibco, Paisley,
UK) supplemented with 10% fetal bovine serum (Hyclone).
Cells were harvested by trypsinization and permeabilized
in buﬀer containing 100mM Tris-HCL (pH 7.5), 150mM
NaCl, 0.5mM MgCl2,1 m MC a C l 2,0 . 2 %B S A ,a n d0 . 1 %
NP-40, followed by staining of DNA with PI/RNase staining
buﬀer (BD Pharmingen, BD Biosciences, San Jose, USA).
Cell suspensions were analyzed by ﬂow cytometry on a
BD FACScalibur (BD Biosciences), to determine G2/M
accumulation as the percentage of cells present in the G2/M
phase of the cell cycle.Anemia 3
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Figure 1: Chromosomal breakage in stimulated T lymphocytes from patients with FA, RBS, or WABS. A chromosomal breakage test,
routinely utilized for the diagnosis of FA, was carried out on various individuals, as indicated (RBS: Roberts syndrome; WABS: Warsaw
Breakage syndrome; FA: Fanconi anemia: FA mosaic, FA patient with hematopoietic mosaicism; Con-1 to -3: healthy controls, that is,
parents of an aﬀected individual; Con-4 and -5: healthy controls, noncarriers; see Table 1). Whole-blood PHA-stimulated T lymphocyte
cultures were exposed to various concentrations of MMC for 72 h and analyzed for chromosomal breakage. Only results for the untreated
(blue bars) and the highest concentration of MMC (300nM, purple bars) are shown. Percentages of cells with the indicated number of
chromatid-type break events per cell are shown.4 Anemia
Table 1: Individuals studied in this report.
Alias Patient code Gene Mutation(s) Remarks ref
RBS-1 VU1199 ESCO2 c.877 878delAG Homozygous [20, 23, 24]
RBS-2 VU1366 ESCO2 c.762 763delTT Homozygous [20, 23, 24]
RBS-3 VU1400 ESCO2 c.877 878delAG Homozygous [20, 23, 24]
RBS-4 VU1174 ESCO2 c.1457 1458delAG Homozygous [20, 23, 24]
WABS VU1202 DDX11 IVS22+2C>T
c.2689 2691delAAG
Compound heterozygous [19]
FA-1 EUFA1333 FANCJ IVS11–498A>T
c.2392C>T
Hematopoietic mosaicism [25]
FA-2 EUFA1386 FANCB c.811insT Hemizygous (X-linked) [26]
Con-1 VU1200 ESCO2 c.877 878delAG Mother of VU1199
Con-2 VU1401 ESCO2 c.877 878delAG Mother of VU1400
Con-3 VU1203 DDX11 IVS22+2C>T Mother of VU1202 [19]
Con-4, -5, -6 Healthy controls
3. Results
3.1. Diagnostic Overlap of FA with RBS in a Chromosomal
Breakage Test. Three RBS patients were included in an
FA-speciﬁc diagnostic test and examined for chromosomal
breakage in PHA-stimulated T lymphocytes. In this test,
lymphocytes of RBS patients RBS-1 and -3 revealed an
MMC-induced excessive increase in chromosomal breakage
events when compared to a healthy control (Figure 1). No
evidence for an excessive chromosomal breakage rate was
found in patient RBS-2. The mean overall breakage rates
(break events per cell) after treatment with the highest MMC
concentration (300nM) were 2.22 in RBS-1, 0.04 in RBS-
2, and 1.4 in RBS-3. Compared to an average of 2.54 break
events per cell in the mosaic FA-J patient (FA-1) and 0.14–
0.22 in the healthy controls, patients RBS-1 and -3 appeared
to fall in the breakage range of mosaic FA patients. In
addition, mono-allelic ESCO2 mutation carriers (mothers of
patients RBS-1 and -3) did not reveal signiﬁcantly increased
chromosomalbreakagerates(Con-1and-2,Figure 1).Muta-
tional analysis revealed a homozygous c.877delAG mutation
i ne x o n4o ft h eESCO2 gene in both RBS-1 and -3, which
was considered remarkable since these individuals were from
unrelated ethnic backgrounds (Turkish and Dutch). Patient
RBS-2 had a c.762delTT mutation in exon 3b.
3.2. Diagnostic Overlap of FA with WABS in a Chromosomal
Breakage Test. The WABS patient was tested for FA, after
he had been excluded from ataxia telangiectasia, Nijmegen
breakage syndrome, and Bloom syndrome [19]. At 150nM
MMC the number of break events in WABS cells was clearly
elevated compared to a healthy control, but somewhat less
pronounced than in FA (data not shown). At the highest
concentration (300nM) the average breakage rate was 8.28
break events/cell, which falls in the range typical for full-
blown FA (Figure 1).
3.3. Diagnostic Overlap of FA with RBS and WABS in a Cell
Cycle Test. Besides the chromosomal breakage test, the FA
Untreated
50nM MMC
100nM MMC
0
10
20
30
40
50
60
RBS-1 RBS-4 WABS FA-1 FA-2 Con-6
C
e
l
l
s
i
n
G
2
/
M
(
%
)
Figure 2: Cell cycle analysis of primary skin ﬁbroblasts from
individuals with FA, RBS, or WABS. Cells were treated with 50 or
100nM MMC, for 72 h. Cell cycle proﬁles were obtained and the
percentagesofcellsinG2/Mphaseofthecellcycleweredetermined.
Averagesofatleasttwoexperimentsareshown,withstandarderrors
of the mean.
diagnosis may also be based upon the increased arrest of
FA cells in G2/M phase of the cell cycle upon treatment
with MMC [4–6]. In this test, primary skin ﬁbroblasts are
exposed to MMC and analyzed by ﬂow cytometry for the
percentage of cells in the G2/M phase of the cell cycle. We
treated primary skin ﬁbroblasts from RBS patients RBS-1
and -4 and the WABS individual with MMC (50 or 100nM)
and analyzed their cell cycle distribution after 72 hours of
drug exposure. In line with the results of the chromosomal
breakage test, both RBS and WABS ﬁbroblasts showed an
increased response to MMC in terms of the extent of their
accumulation in G2/M compared to ﬁbroblasts from a
healthy control individual (Figure 2). Concordant with the
chromosomal breakage test, the response to MMC in the
WABS patient was similar to that in FA (approximately 50%Anemia 5
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Figure 3: (a) Cohesion defects in lymphocyte cultures from patients with FA, RBS, or WABS. Metaphases prepared from untreated cultures
(−) or treated with 150nM MMC (+) which had previously been evaluated for chromosomal breakage were reevaluated for the presence of
cohesion defects. The percentages of cells containing the indicated number of railroad chromosomes (RR) or total premature centromere
separation (PCS) were determined, as summarized in the histograms. (b) Illustrations of the various aberrations scored in the analysis.
of the cells in G2/M at 100nM MMC). The least pronounced
response was observed in RBS patient RBS-1 (38% in G2/M,
Figure 2), which seemed to correlate with the moderate
breakage rate observed in the chromosomal breakage test.
However, as illustrated by patient RBS-4, some cases with
RBS may behave as a genuine FA case in a cell cycle analysis
test (48% in G2/M; Figure 2).
3.4. Cohesion Defects Distinguish RBS and WABS from FA.
Next to the increased chromosomal breakage and G2/M
arrest after MMC treatment in RBS and WABS cells,
another clear phenotype was seen at the chromosomal level.
Metaphases of the primary lymphocyte cultures showed
a drastic increase in the occurrence of cohesion defects
(railroad-track chromosomes) in the untreated RBS and
WABS patient cells, which were not found in the heterozy-
gous carriers, healthy controls, FA, and FA mosaic patients
(Figure 3(a)). The RBS and WABS patients revealed the
presence of >5 railroad chromosomes in 79%–98% of the
metaphases,whileinthecontrols,heterozygotes,andFAcells
this percentage did not exceed 2% of the cells. In addition
to the railroad chromosomes cells from the WABS patient
showed a massive increase in the total premature sister
chromatid separation in response to treatment with MMC
at 150nM. Although untreated FA lymphocyte cultures had
normal chromatid cohesion, MMC treatment resulted in a
signiﬁcant cohesion defect in FA lymphocyte cultures as well
(FA-1and-2,Figure 3(a)),albeitthatthisdefectbecameonly
manifest as railroad chromosomes, without the occurrence
of PCS.
4. Discussion
Although hypersensitivity to MMC and DEB in peripheral
blood lymphocytes is an accepted diagnostic criterion for
FA, this study shows that in addition to Nijmegen breakage
syndrome, also patients with RBS or WABS cells may
scorepositive inanFA-speciﬁcMMC-inducedchromosomal
breakage test or in an MMC-induced G2/M arrest analysis.
These aﬀected individuals might have been diagnosed as
FA patients (with hematopoietic mosaicism) on the basis
of their clinical characteristics in combination with their6 Anemia
hypersensitivity to MMC. However, detailed inspection of
metaphases for chromosomal cohesion defects and subse-
quent mutational analysis of the ESCO2 or DDX11 genes
would have demonstrated that these patients were to be
diagnosed as RBS or WABS, respectively.
Next to RBS and WABS, a third cohesinopathy has been
known, called Cornelia de Lange syndrome (CdLS). This
syndrome is caused by mutations in cohesin complex com-
ponents (SMC1A and SMC3) or its regulatory factor NIPBL
[28–31]. CdLS is a multisystem developmental disorder
with classical features of characteristic facial dysmorphisms,
upper limb malformations, hirsutism, and growth and
cognitive retardation displaying a wide spectrum of clinical
severity. Studies have revealed an increased sensitivity to
MMC for both ﬁbroblasts and B lymphoblastoid cells of
CdLS patients [17], which indicates that CdLS patients may
also score positive in an FA-speciﬁc diagnostic test leading to
a possible diagnostic overlap with this cohesinopathy as well.
However, due to the quite characteristic facial appearance
of CdLS patients, the chance for a CdLS patient being
misdiagnosed as FA seems very small.
Interestingly,bothRBSpatientswithac.877delAGmuta-
tion showed hypersensitivity for chromosomal breakage by
MMC, while the patient with a diﬀerent mutation had no
such hypersensitivity. All ESCO2 mutations found until now
in RBS patients have appeared to aﬀect the acetyltransferase
activity of the protein [23]. Patient RBS-1 was strongly
aﬀected,withseverelyshortenedarmsandlegsandacleftlip.
Despite the fact that the patients carried the same mutations
(without evidence for a common ancestry), the clinical
phenotype of patient RBS-3 was much milder. In this case,
patient RBS-3 might have been suspected to have FA, and in
combination with the increased MMC sensitivity could have
been misdiagnosed as FA. These observations also indicate
that there is no obvious correlation between the severity of
disease symptoms and the extent of sensitivity to DNA cross-
linking agents and support the notion that there is no clear
genotype-phenotype correlation in RBS [22].
This report has conﬁrmed that the test for chromosomal
hypersensitivity to DNA cross-linking agents is not entirely
speciﬁc for FA: in addition to Nijmegen Breakage syndrome
both RBS and WABS patient cells also show increased
sensitivity to MMC. It is therefore to be recommended that
in the cytogenetic diagnosis of FA, particularly in clinically
atypical patients, quantiﬁcation of chromosomal cohesion
defects is included in the analysis.
In conclusion, although some of the clinical charac-
teristics and the extent of MMC-induced chromosomal
breakage in RBS and WABS T lymphocytes show overlap
with those of (mosaic) FA patients, inspection of metaphase
chromosomes for premature centromere division (PCD,
railroadchromosomes)andprematurechromatidseparation
(PCS) allows to distinguish RBS and WABS from FA.
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